Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Other Accumulated Expenses: 2022-2024

  • Immunocore Holdings' Other Accumulated Expenses was N/A to $7.5 million in Q1 2024 from the same period last year, while for Mar 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $6.0 million for FY2023, which is 62.74% up from last year.
  • Latest data reveals that Immunocore Holdings reported Other Accumulated Expenses of $7.5 million as of Q1 2024, which was up 24.49% from $6.0 million recorded in Q4 2023.
  • Immunocore Holdings' 5-year Other Accumulated Expenses high stood at $7.5 million for Q1 2024, and its period low was $3.7 million during Q4 2022.
  • Its 3-year average for Other Accumulated Expenses is $5.7 million, with a median of $6.0 million in 2023.
  • Data for Immunocore Holdings' Other Accumulated Expenses shows a peak YoY surged of 62.74% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunocore Holdings' Other Accumulated Expenses stood at $3.7 million in 2022, then spiked by 62.74% to $6.0 million in 2023, then reached $7.5 million in 2024.
  • Its Other Accumulated Expenses stands at $7.5 million for Q1 2024, versus $6.0 million for Q4 2023 and $3.7 million for Q4 2022.